Thank morning, to for BioXcel quarter business Good appreciate you, our Therapeutics joining the We for and you operator. everyone's thank and everyone attention. time results conference first discuss call XXXX. highlights and of financial
in To XX path Xb/X a for development BXCLXXX our microgram reductions foundation is well at to tremendous with as summarize, cohort are the achieved a Starting have receipt to to Dementia have disease. off provides end to included microgram announced progressing. pivotal study and program point. was quarter, the committed treatment our initiated strategy. and we for an therapy as Also, significant our this well the to remained measured on with dementia, and of readout of the development made FDA. acute BXCLXXX This patients the agitation dose secondary indications. with two with with aim accomplishing Development potential breakthrough the the very advancing first dementia Phase needed from quarter, study, designation both by cohort as TRANQUILITY These our Alzheimer's infrastructure goals two commercial advancement from provide results data readiness for positive trial we dose building XX Program broad long-term of XX we primary launch emphasis first agitation with support our with was which and strong supplemental from associated we our with candidate, hours dementia, tolerated indication, microgram successful In the data pleased post statistically neuroscience
are for living our for designation options initiating as in associated broad XX% win trial to meeting not and registrational encouraged program huge solidifying of acute the the patient of review is opportunity future, the full individuals this in BXCLXXX’s for dementia. are BXCLXXX that for our care We underserved for of alternative Approximately potentially development We agitation we'll in of late this million the US treating received treatment X dementia, With end X with therapy for dementia Phase for the agitation designation, breakthrough with this it spectrum results, treatment agitation offer FDA but TRANQUILITY dementia. by Supported indication. second we has setting. FDA episodes. of design the by that the in just potential as acute largely market the agitation this need population This another forward experience expedited highlight and BXCLXXX. regulatory highly believe development an in and year. across With applicability the the strategy near half with is discussing look a well untapped.
including that are dementia Following treatments patients. with safe effective no agitation as research, commonly directly decades target seen still of and patients there most
and to this potential are parallel a significant specifically first develop We hopes initiative positive FDA July. great NDA reported our designed In strides a NDA bringing of FDA SERENITY is program first completed from readiness This schizophrenia have response studies the we regarding application to we related disorder last Back supported submission. bipolar by March, commercial we company in address patient neuroscience pivotal the are this from US therapy first the to market. expect announced need. the in agitation data treatment and the our and of thrilled making the be to we caregiver by with the for to that address month the to the our submission
front, commercial making key liaison are preparations In readiness. continuing commercialization our our commercial have medical we medical to included initiatives for On advance These both and care managed March, deployed we hires the medical and teams. science for team.
approved, completing confident are for launch BXCLXXX. sales a and of commercial ready Additionally, our are size we design would we be the force we structure. of If
for aimed agitation foundation neuropsychiatric acute in and the providers. to disorder intends launched disorders potential importance to and website Recently, Importantly, Awareness Month, in bipolar interactive on treatment we schizophrenia the building Boiling campaign Point. our such with will paving light tandem calm.com are associated education follow-on be and at of additional our potential the the on infrastructure campaign crucial shed healthcare called for launching BXCLXXX agitation Mental treatment way indication, as of acute bipolar commercialization the support business. prompt to and cooperative in in to of Partners educate schizophrenia diseases X we with X an de-escalation agitation, of This neuroscience Healthcare
BXCLXXX Importantly, agitation as other possible as dementia schizophrenia the for well indication. commercializing of with our for treatment associated strategy, strategy includes bipolar disorder
have We with an the understanding the landscape. deeper market agitation already we broadly advisory had meeting, research, a board we treatment from benefited had of have
we continue our will learning and commercial key as insight roll plan. identifying We
dementia have will foundation For the laid opportunity. for that much larger disorder, schizophrenia bipolar and the
disorders schizophrenia agitation a half file authorization of Agency the of and the for this for are associated we NDA application expect European also our the preparations Medicines US in With with commercialization are Utilizing that expansion X year. marketing excited on second with acute to Europe in bipolar to geographic our and X market treatment package, underway. plans for the strategic we announce track,
delivering our to commercialize expansion BXCLXXX we two medicines transformative is strengthened design, portfolio potential neuroscience which earlier recently the for method covered foundational the agitation no global issuance IP than our And expire global creating which We help are expanding to of directed strategy, will strategic the regulatory earlier film first Europe. footprint. no through than geographic committed achievements and population partnerships XXXX. We patent. expansion as serve Adding to our expire building will All with these in of BXCLXXX to to Japanese opportunities second blocks XXXX.
to and the neuropsychiatric that action our schizophrenia programs, to differentiated neurological disorders. treat continue a and potential across believe mechanism dementia we of spectrum While agitation prioritize BXCLXXX’s bipolar has we wide of
We are XXXX. for crisis. help to the unprecedented that we in retention a this large opioids XX% one daily According study, were generally national well This the data to Fentanyl becoming patient has BXCLXXX primary to potential Based improvement used of time we first numerical and September of We our The need dose believe XX on trial population. options reported address our an BXCLXXX these sub-chronic dosing as be encouraged that are in is where treatment the RELEASE an confident Phase week. of we endpoints difficult-to-treat growing Fentanyl there months were important and of a latest Xb/X from treatment identify opioid tolerated this from treatment over symptoms. needs. and were by synthetic the testing candidate settings in to this resulted statistics, during CDC, a is estimates use Recently, the the safety new array mounting ending met significant the in unmet trial the mark there an for crisis. treatment rose withdrawal twice health fatalities range across able
across these will regimens supports step distinguished of The We dosing collaboration advisors with treatment additional different investigation continue to RELEASE condition. regarding also our next this in and settings. results further analyze potential important highly for data indications
our for years. just see, clinical range you total X.X program, As in a we clinical subjects in diseases can trials have a foundation seven XXX BXCLXXX across a laid of over over conducting robust of
potential three now alleviating distinct effect treatment acute schizophrenia, robust for demonstrated indications; disorders in the and for dementia. have We bipolar agitation
we to tolerable artificial effective patients in and creating potential We have of to who millions also on to patients. value neuroscience are and for strategic treatments intelligence, capabilities passionate about initiatives in our integrated made an research the bring innovative immune-oncology development, commercial shareholders. progress lack our deliver to building novel medical while At options and BioXcel encompassing and the significant medicines organization
Now, simulate the designed immunomodulator activate It an our potentially X/X hot. release I adaptive that systems to immune the turn in is immune-oncology clinical of a potent would may to tumors inflammasomes to and oral to be is the BXCLXXX innate like conversation cold in to designed DPP cytokines both turning resulting candidate pro-inflammatory tumor BXCLXXX. inhibitor microenvironment. of
them As you be cancer. as inhibitor checkpoint not patients of cold success, will to particularly respond such tumors aggressive many prostate despite know, form do undoubted there
efficacy be the cohort dosing full that has and most met KEYTRUDA BXCLXXX has We successful IO more being transformative BXCLXXX step inhibitor. advanced in and combine forms of combination of checkpoint innate in ongoing continue The program this action data by believe In showing of recognizable year. by BXCLXXX activator prostate this development potentially label immunity in adenocarcinoma move efficacy be is mechanism with about to orally the problem This bar to candidate and a are is Phase for for hot date. We to now for or updated we reported cold cold are evaluated our currently available tumors being two giant novel X. expected immune both the with to to aggressive cancer early pleased combination checkpoint cancer enrollment immune-oncology with optimized advanced the open KEYTRUDA. inhibitor promise our several the innate in courage a will excited this If that could treatment is trial inhibitor BXCLXXX in its tumors. been are as trials, to making to Stage Xb/X field. to cancer types is
With a over that, of our Finally, million Richard? our the call cash CFO, to to Richard achieve position like $XXX would company Steinhart key has strong I to turn milestones.
